Skandinaviska Enskilda Banken AB publ lifted its stake in HCA Healthcare Inc (NYSE:HCA) by 75.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 83,585 shares of the company’s stock after purchasing an additional 36,000 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in HCA Healthcare were worth $11,628,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. State of Alaska Department of Revenue lifted its holdings in HCA Healthcare by 27.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 45,700 shares of the company’s stock worth $4,687,000 after buying an additional 9,910 shares in the last quarter. Confluence Investment Management LLC acquired a new position in HCA Healthcare during the 2nd quarter worth $283,000. NN Investment Partners Holdings N.V. lifted its holdings in HCA Healthcare by 198.9% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 170,204 shares of the company’s stock worth $17,463,000 after buying an additional 113,265 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in HCA Healthcare during the 2nd quarter worth $259,000. Finally, Bank of Montreal Can lifted its holdings in HCA Healthcare by 49.5% during the 2nd quarter. Bank of Montreal Can now owns 506,077 shares of the company’s stock worth $51,922,000 after buying an additional 167,599 shares in the last quarter. Hedge funds and other institutional investors own 70.84% of the company’s stock.
HCA stock opened at $143.95 on Friday. The firm has a market capitalization of $48.75 billion, a PE ratio of 15.92, a P/E/G ratio of 1.24 and a beta of 0.48. HCA Healthcare Inc has a twelve month low of $74.26 and a twelve month high of $144.18.
HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $2.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.23. The company had revenue of $11.45 billion for the quarter, compared to the consensus estimate of $11.29 billion. HCA Healthcare had a negative return on equity of 73.71% and a net margin of 6.82%. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.13 EPS. Sell-side analysts forecast that HCA Healthcare Inc will post 9.35 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Monday, December 3rd will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Friday, November 30th. HCA Healthcare’s dividend payout ratio (DPR) is currently 21.24%.
In other news, insider Michael S. Cuffe sold 4,943 shares of the stock in a transaction on Friday, November 9th. The stock was sold at an average price of $141.90, for a total value of $701,411.70. Following the transaction, the insider now owns 33,240 shares of the company’s stock, valued at approximately $4,716,756. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jane D. Englebright sold 6,543 shares of the stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $129.86, for a total value of $849,673.98. Following the completion of the transaction, the senior vice president now directly owns 7,443 shares in the company, valued at approximately $966,547.98. The disclosure for this sale can be found here. In the last three months, insiders sold 22,486 shares of company stock worth $3,079,086. 2.80% of the stock is currently owned by company insiders.
Several research firms have issued reports on HCA. JPMorgan Chase & Co. upped their price objective on HCA Healthcare to $151.00 and gave the stock an “overweight” rating in a report on Monday, July 30th. SunTrust Banks upped their price objective on HCA Healthcare to $150.00 and gave the stock a “positive” rating in a report on Tuesday, September 4th. Mizuho reaffirmed a “buy” rating and set a $145.00 price objective on shares of HCA Healthcare in a report on Thursday, August 2nd. Leerink Swann upped their price objective on HCA Healthcare from $125.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Finally, Argus upped their price objective on HCA Healthcare to $150.00 and gave the stock a “buy” rating in a report on Friday, September 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $141.53.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Featured Article: Marijuana Stocks Future Looks Bright
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.